Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
MENLO PARK, Calif., March 01, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 8:40 a.m. ET on Tuesday, March 8, 2016, in Boston. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Investor Contact Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]
